

ANTICANCER RESEARCH

International Journal of Cancer Research and Treatment

ISSN: 0250-7005

Volume 36, Number 11, November 2016
Special Issue on New Anticancer Agents

Contents

Reviews

- MicroRNAs: A Puzzling Tool in Cancer Diagnostics and Therapy. B. D'ANGELO, E. BENEDETTI, A. CIMINI, A. GIORDANO (*Philadelphia, PA, USA; L'Aquila; Assergi; Siena, Italy*) 5571
- Therapeutic Innovations for Targeting Hepatoblastoma. A. GARNIER, M. ILMER, R. KAPPLER, M. BERGER (*Munich, Germany; Atlanta, GA, USA*) 5577
- Cancer Immunology and Immunotherapy. A. SUKARI, M. NAGASAKA, A. AL-HADIDI, L.G. LUM (*Detroit; Royal Oak, MI; Charlottesville, VA, USA*) 5593
- Immune Blockade Inhibition in Breast Cancer. I.A. VOUTSADAKIS (*Sudbury, ON, Canada*) 5607
- Discovery of Anticancer Agents of Diverse Natural Origin. A.D. KINGHORN, E.J. CARCACHE DE BLANCO, D.M. LUCAS, H.L. RAKOTONDRAIBE, J. ORJALA, D.D. SOEJARTO, N.H. OBERLIES, C.J. PEARCE, M.C. WANI, B.R. STOCKWELL, J.E. BURDETTE, S.M. SWANSON, J.R. FUCHS, M.A. PHELPS, L. XU, X. ZHANG, Y.Y. SHEN (*Columbus, OH; Chicago, IL; Greensboro; Hillsborough; Research Triangle Park, NC; New York, NY; Madison, WI; Andover, MA, USA*) 5623
- Molecular Mechanisms of Anti-metastatic Activity of Curcumin. Y. DENG, E. VERRON, R. ROHANIZADEH (*Sydney, Australia; Nantes, France*) 5639
- The Antitumor Effect of Singlet Oxygen. G. BAUER (*Freiburg, Germany*) 5649
- Identification of Important Compounds Isolated from Natural Sources that Have Activity Against Multidrug-resistant Cancer Cell Lines: Effects on Proliferation, Apoptotic Mechanism and the Efflux Pump Responsible for Multi-resistance Phenotype. L. AMARAL, G. SPENGLER, J. MOLNÁR (*Szeged, Hungary; Lisbon, Portugal*) 5665

Contents continued on the back cover

Regulation of the Expression of Cytoplasmic Polyadenylation Element Binding Proteins for the Treatment of Cancer. Y. CHEN, Y.-H. TSAI, S.-H. TSENG (<i>New Taipei; Taoyuan; Taipei, Taiwan, ROC</i>)	5673
Targeting Cellular Signaling Pathways in Breast Cancer Stem Cells and its Implication for Cancer Treatment. B.R.B. PIRES, Í.S.S. DE AMORIM, L.D.E. SOUZA, J.A. RODRIGUES, A.L. MENCALHA (<i>Rio de Janeiro, RJ, Brazil</i>)	5681
Heart Peptide Hormones: Adjunct and Primary Treatments of Cancer. D.L. VESELY (<i>Tampa, FL, USA</i>)	5693
The Anticancer Activity of the Old Neuroleptic Phenothiazine-type Drug Thioridazine. G. SPENGLER, Á. CSONKA, J. MOLNÁR, L. AMARAL (<i>Szeged, Hungary; Lisbon, Portugal</i>)	5701
Potential Anti-metastasis Natural Compounds for Lung Cancer. P. CHANVORACHOTE, S. CHAMNI, C. NINSONTIA, P.P. PHIBOONCHAIYANAN (<i>Bangkok, Thailand</i>)	5707
Radium-223: Insight and Perspectives in Bone-metastatic Castration-resistant Prostate Cancer. F.E. BURONI, M.G. PERSICO, F. PASI, L. LODOLA, R. NANO, C. APRILE (<i>Pavia, Italy</i>)	5719
<i>Experimental Studies</i>	
The Effects of Histone Deacetylase Inhibitor and Calpain Inhibitor Combination Therapies on Ovarian Cancer Cells. K. LAPINSKA, G. HOUSMAN, S. BYLER, S. HEERBOTH, A. WILLBANKS, A. OZA, S. SARKAR (<i>Boston, MA; North Haven, CT; Tempe, AZ; Nashville, TN, USA</i>)	5731
Vanillin Analogues <i>o</i> -Vanillin and 2,4,6-Trihydroxybenzaldehyde Inhibit NFκB Activation and Suppress Growth of A375 Human Melanoma. A. MARTON, E. KÚSZ, C. KOLOZSI, V. TUBAK, G. ZAGOTTO, K. BUZÁS, L. QUINTIERI, C. VIZLER (<i>Szeged, Hungary; Padua, Italy</i>)	5743
ITPP Treatment of RG2 Glioblastoma in a Rat Model. K. FÖRNVIK, S. ZOLFAGHARI, L.G. SALFORD, H.N. REDEBRANDT (<i>Lund, Sweden</i>)	5751
Antioxidant and Antiproliferative Properties of the Essential Oils of <i>Satureja thymbra</i> and <i>Satureja parnassica</i> and their Major Constituents. E. FITSIOU, I. ANESTOPOULOS, K. CHLICHLIA, A. GALANIS, I. KOURKOUTAS, M.I. PANAYIOTIDIS, A. PAPPÁ (<i>Alexandroupolis, Greece; Edinburgh, Scotland, UK</i>)	5757
Targeting the PI3K/PTEN/AKT/mTOR Pathway in Treatment of Sarcoma Cell Lines. H.J. LIM, X. WANG, P. CROWE, D. GOLDSTEIN, J.-L. YANG (<i>Randwick, NSW, Australia</i>)	5765
Secreted Phosphoprotein 24 kD Inhibits Growth of Human Prostate Cancer Cells Stimulated by BMP-2. L. LAO, J. SHEN, H. TIAN, Q. YAO, Y. LI, L. QIAN, S.S. MURRAY, J.C. WANG (<i>Shanghai, PR China; Los Angeles; Sepulveda, CA, USA</i>)	5773
The Use of Toll-like Receptor 4 Agonist to Reshape the Immune Signature in Ovarian Cancer. E. VINDEVOGEL, T. BAERT, A. VAN HOYLANDT, G. VERBIST, G. VANDE VELDE, A.D. GARG, P. AGOSTINIS, I. VERGOTE, A. COOSEMANS (<i>Leuven, Belgium</i>)	5781
<i>In Vitro</i> Generation of Murine Dendritic Cells for Cancer Immunotherapy: An Optimized Protocol. T. BAERT, A.D. GARG, E. VINDEVOGEL, A. VAN HOYLANDT, G. VERBIST, P. AGONISTINIS, I. VERGOTE, A. COOSEMANS (<i>Leuven, Belgium</i>)	5793
Quantitative Structure-cytotoxicity Relationship of 3-Benzylidenechromanones. Y. UESAWA, H. SAKAGAMI, H. KAGAYA, M. YAMASHITA, K. TAKAO, Y. SUGITA (<i>Kiyose; Sakado, Japan</i>)	5803
Negative Impact of Total Body Irradiation on the Antitumor Activity of Rhenium-(I)-diselenoether. P. COLLERY, F. SANTONI, A. MOHSEN, C. MIGNARD, D. DESMAELE (<i>Algajola; Bastia; Châtenay-Malabry; Dijon, France</i>)	5813

Pulsed Electromagnetic Field with Temozolomide Can Elicit an Epigenetic Pro-apoptotic Effect on Glioblastoma T98G Cells. F. PASI, L. FASSINA, M.E. MOGNASCHI, G. LUPO, F. CORBELLA, R. NANO, E. CAPELLI (<i>Pavia, Italy</i>)	5821
Isoflavone Extracts Enhance the Effect of Epidermal Growth Factor Receptor Inhibitors in NSCLC Cell Lines. R. AMBROSIO, M.N. OMBRA, C. GRIDELLI, G. PICARIELLO, M. DI STASIO, M.G. VOLPE (<i>Avellino, Italy</i>)	5827
Monensin Induces PC-3 Prostate Cancer Cell Apoptosis <i>via</i> ROS Production and Ca ²⁺ Homeostasis Disruption. S.-H. KIM, K.-Y. KIM, S.-N. YU, S.-G. PARK, H.-S. YU, Y.-K. SEO, S.-C. AHN (<i>Yangsan; Gyeongsan; Ulsan, Republic of Korea</i>)	5835
Selective Toxicity of a Highly Potent Camptothecin Analogue: A Pilot Study with Glioblastoma Multiforme Cells. G. YOUNT, L. SOROCEANU, H.-J. WANG, E. SINGER, R. YOUNT, T. LUU, L.-X. YANG (<i>San Francisco, CA, USA</i>)	5845
Co-treatment of LY294002 or MK-2206 with AZD5363 Attenuates AZD5363-induced Increase in the Level of Phosphorylated AKT. A.-R. CHOI, J.-H. KIM, Y.H. WOO, J.H. CHEON, H.S. KIM, S. YOON (<i>Goyang-si; Suwon, Republic of Korea</i>)	5849
Attenuation of Colchicine Toxicity in Drug-resistant Cancer Cells by Co-treatment with Anti-malarial Drugs. A.-R. CHOI, J.-H. KIM, J.H. CHEON, H.S. KIM, S. YOON (<i>Goyang-si; Suwon, Republic of Korea</i>)	5859
Highly Halaven-resistant KBV20C Cancer Cells Can Be Sensitized by Co-treatment with Fluphenazine. J.H. CHEON, B.M. LEE, H.S. KIM, S. YOON (<i>Suwon, Republic of Korea</i>)	5867
Therapeutic Effects of Hybrid Liposomes Against Xenograft Mouse Model of Colorectal Cancer <i>In Vivo</i> Due to Long-term Accumulation. H. ICHIHARA, M. OKUMURA, Y. MATSUMOTO (<i>Kumamoto, Japan</i>)	5875
Minodronic Acid in Combination with $\gamma\delta$ T Cells Induces Apoptosis of Non-small Cell Lung Carcinoma Cell Lines. M. YASUKAWA, T. NAKAZAWA, T. KAWAGUCHI, N. KAWAI, T. TSUJIMURA, T. TOJO, S. TANIGUCHI (<i>Kashihara; Uda, Japan</i>)	5883
Ad-shWnt2b Vector Therapy Demonstrates Antitumor Activity in Orthotopic Intrapleural Models as Monitored with the <i>In Vitro</i> Imaging System (IVIS). M. KOBAYASHI, C.-L. HUANG, M. SONOBE, R. KIKUCHI, H. DATE (<i>Tokyo; Kyoto, Japan</i>)	5887
The Behavior and Role of Lipolysis-stimulated Lipoprotein Receptor, a Component of Tricellular Tight Junctions, in Head and Neck Squamous Cell Carcinomas. K. TAKANO, T. KAKUKI, K. OBATA, K. NOMURA, R. MIYATA, A. KONDO, M. KUROSE, A. KAKIUCHI, Y. KANEKO, T. KOHNO, T. HIMI, T. KOJIMA (<i>Sapporo, Japan</i>)	5895
Tamoxifen Suppresses the Growth of Malignant Pleural Mesothelioma Cells. C.J. JENNINGS, N. ZAINAL, I.M.M. DAHLAN, E.W. KAY, B.J. HARVEY, W. THOMAS (<i>Dublin, Ireland; Selangor, Malaysia</i>)	5905
New Treatment Options for Osteosarcoma – Inactivation of Osteosarcoma Cells by Cold Atmospheric Plasma. D. GÜMBEL, N. GELBRICH, M. WEISS, M. NAPP, G. DAESCHLEIN, A. SCKELL, S.A. ENDER, A. KRAMER, M. BURCHARDT, A. EKKERNKAMP, M.B. STOPE (<i>Greifswald; Berlin, Germany</i>)	5915
Gimeracil Exerts Radiosensitizing Effects on Oral Squamous Cell Carcinoma Cells <i>In Vitro</i> and <i>In Vivo</i> . K. HARADA, T. FERDOUS, Y. UEYAMA (<i>Ube, Japan</i>)	5923
Cytotoxic Components Against Human Oral Squamous Cell Carcinoma Isolated from <i>Andrographis paniculata</i> . R. SUZUKI, Y. MATSUSHIMA, N. OKUDAIRA, H. SAKAGAMI, Y. SHIRATAKI (<i>Sakado, Japan</i>)	5931

Cell Surface Antibody Retention Influences <i>In Vivo</i> Antitumor Activity Mediated by Antibody-dependent Cellular Cytotoxicity. M. IKEDA, K. KATO, M. YAMAGUCHI, H. HAMADA, K. NAKAMURA, Y. SUGIMOTO (<i>Machida-shi; Kawagoe; Sapporo; Hachioji, Japan</i>)	5937
The Antitumor Effect of Single-domain Antibodies Directed Towards Membrane-associated Catalase and Superoxide Dismutase. G. BAUER, M. MOTZ (<i>Freiburg; Neuried, Germany</i>)	5945
Investigation of Bioequivalence Between Brand-name and Generic Irinotecan Products. K.-I. SAITO, Y. INOUE, Y. IKEGAMI, I. NANBO, M. ONOZUKA, K. SANNO, H. YOSHIDA, T. SAKAMOTO, E. TATEBAYASHI, K.-I. FUJITA, Y. SASAKI, T. KITAZAWA (<i>Saitama; Kiyose; Tokyo; Moroyama, Japan</i>)	5957
Novel Synthetic Mono-triazole Glycosides Induce G ₀ /G ₁ Cell-cycle Arrest and Apoptosis in Cholangiocarcinoma Cells. S. OBCHOEI, R. SAEENG, C. WONGKHAM, S. WONGKHAM (<i>Khon Kaen; Chonburi, Thailand</i>)	5965
Enhancing the Therapeutic Efficacy of 2-Deoxyglucose in Breast Cancer Cells Using Cell-cycle Synchronization. S.J. LEE, B.-N. PARK, J.H. ROH, Y.-S. AN, H. HUR, J.-K. YOON (<i>Suwon, Republic of Korea</i>)	5975
Potential of Selenium Compounds as New Anticancer Agents for Cholangiocarcinoma. X. DAI, S. THONGCHOT, H. DOKDUANG, W. LOILOME, N. KHUNTIKEO, A. TITAPUN, P. UNGARREEVITTAYA, P. YONGVANIT, A. TECHASEN, N. NAMWAT (<i>Khon Kaen, Thailand</i>)	5981
Cantharidin Impairs Cell Migration and Invasion of Human Lung Cancer NCI-H460 Cells <i>via</i> UPA and MAPK Signaling Pathways. T.-C. HSIA, C.-C. YU, Y.-T. HSIAO, S.-H. WU, D.-T. BAU, H.-F. LU, Y.-P. HUANG, J.-G. LIN, S.-J. CHANG, J.-G. CHUNG (<i>Taichung; Changhua; Taipei, Taiwan, ROC</i>)	5989
<i>In Vitro</i> and <i>In Vivo</i> Anticancer Activity of Human β -Defensin-3 and Its Mouse Homolog. Y. HANAOKA, Y. YAMAGUCHI, H. YAMAMOTO, M. ISHII, T. NAGASE, H. KURIHARA, M. AKISHITA, Y. OUCHI (<i>Tokyo, Japan</i>)	5999
Anticancer Effects of a New Aminosugar-conjugated Platinum Complex Agent Against Cisplatin-resistant Gastric Cancer. N. HAYASHI, H. KATAOKA, S. YANO, J.-I. KIKUCHI, M. TANAKA, H. NISHIE, Y. KINOSHITA, M. HATANO, A. NOMOTO, A. OGAWA, M. INOUE, T. MIZOSHITA, T. SHIMURA, Y. MORI, E. KUBOTA, S. TANIDA, T. JOH (<i>Nagoya; Nara; Kyoto; Osaka, Japan</i>)	6005
Inhibition of the Pentose-phosphate Pathway Through 6-Aminonicotinamide-sensitized Leukemia Lymphocytes, but not Normal Lymphocytes, to Chemotherapeutics by a ROS-independent Mechanism. Z. ZHELEV, D. IVANOVA, R. BAKALOVA, I. AOKI, T. HIGASHI (<i>Stara Zagora; Sofia, Bulgaria; Chiba, Japan</i>)	6011
Inhibition of Glutaminolysis Inhibits Cell Growth <i>via</i> Down-regulating Mtorc1 Signaling in Lung Squamous Cell Carcinoma. X. YE, Q. ZHOU, Y. MATSUMOTO, M. MORIYAMA, S. KAGEYAMA, M. KOMATSU, S. SATOH, M. TSUCHIDA, Y. SAIJO (<i>Niigata, Japan</i>)	6021
Norcantharidin-induced Apoptosis of AGS Human Gastric Cancer Cells Through Reactive Oxygen Species Production, and Caspase and Mitochondria-dependent Signaling Pathways. L.-C. ZHENG, M.-D. YANG, C.-L. KUO, C.-H. LIN, M.-J. FAN, Y.-C. CHOU, H.-F. LU, W.-W. HUANG, S.-F. PENG, J.-G. CHUNG (<i>Taichung; Taipei, Taiwan, ROC</i>)	6031
Dibenzoyl-methane Derivatives as a Potential and Exciting New Therapy for the Treatment of Childhood Bone Cancer. E. ALMELAH, D.P.T. SMITH, A. MCGOWN, A. AZIZ, H.J. POTGIETER, P. RAGAZZON (<i>Manchester, UK</i>)	6043
Dose Effect of Rhenium (I)-diselenoether as Anticancer Drug in Resistant Breast Tumor-bearing Mice After Repeated Administrations. P. COLLERY, F. SANTONI, J. CICCOLINI, T.N.N. TRAN, A. MOHSEN, D. DESMAELE (<i>Algajola; Bastia; Marseille; Malabry, France</i>)	6051

Apoptosis of Hepatitis B Virus-expressing Liver Tumor Cells Induced by a High Concentration of Nucleos(t)ide Analogue. E. TAK, S. HWANG, H.C. LEE, G.-Y. KO, C.-S. AHN, Y.-I. YOON, Y.-S. LIM, D.-Y. JUN, K.-H. KIM, G.-W. SONG, D.-B. MOON, B.-Y. RYOO, N. KIM, S.-G. LEE (<i>Seoul, Republic of Korea</i>)	6059
Blockade of Androgen-induced Malignant Phenotypes by Flutamide Administration in Human Salivary Duct Carcinoma Cells. Y. KAMATA, T. SUMIDA, R. MURASE, H. NAKANO, T. YAMADA, Y. MORI (<i>Fukuoka; Toon, Japan</i>).....	6071
Antitumor Effects of Eribulin Mesylate in Gemcitabine-resistant Pancreatic Cancer Cell Lines. Y. TAKEZAKI, T. NAMIKAWA, T. KOYAMA, E. MUNEKAGE, M. MUNEKAGE, H. MAEDA, H. KITAGAWA, K. HANAZAKI (<i>Kochi, Japan</i>).....	6077
Impact of H3K27 Demethylase Inhibitor GSKJ4 on NSCLC Cells Alone and in Combination with Metformin. H. WATARAI, M. OKADA, K. KURAMOTO, H. TAKEDA, H. SAKAKI, S. SUZUKI, S. SEINO, H. OIZUMI, M. SADAHIRO, C. KITANAKA (<i>Yamagata, Japan</i>).....	6083
Effect of Olmesartan on the Level of Oral Cancer Risk Factor PAI1. S. VASSILIOU, E. NKENKE, N. LEFANTZIS, A. IOANNIDIS, C. YAPIJAKIS, M. ZOGA, V. PAPAKOSTA, S. DERKA, C. NIKOLAOU, E. VAIRAKTARIS (<i>Athens; Sparta, Greece; Vienna, Austria</i>).....	6093
FoxO3a is Essential for the Antiproliferative and Apoptogenic Effects of Sunitinib in MDA-MB231 Cell Line. H.M. KORASHY, O.M. BELALI, M.A. ANSAR, N.O. ALHARBI (<i>Riyadh, Kingdom of Saudi Arabia</i>)	6097
Fisetin Reduces Cell Viability Through Up-Regulation of Phosphorylation of ERK1/2 in Cholangiocarcinoma Cells. N. KIM, S.H. LEE, J.H. SON, J.M. LEE, M.-J. KANG, B.H. KIM, J.-S. LEE, J.K. RYU, Y.-T. KIM (<i>Seoul; Changwon, Republic of Korea</i>)	6109
Peroxisome Proliferator-activated Receptors as Potential Targets for Carcinogenic Activity of Polychlorinated Biphenyls: A Computational Perspective. I.A. SHEIKH, A.A. KHWEEK, M.A. BEG (<i>Jeddah, Kingdom of Saudi Arabia; Birzeit, Palestine</i>).....	6117
<i>In Silico</i> Identification of Novel Erlotinib Analogues Against Epidermal Growth Factor Receptor. I.A. SHEIKH, H.M.A. HASSAN (<i>Jeddah, Kingdom of Saudi Arabia</i>)	6125
A Novel Aziridine-based Bruton's Tyrosine Kinase Inhibitor Induces Apoptosis Through Down-regulation of p65/RelA Phosphorylation on Serine 536 and ERK1/2 in Mantle Cell Lymphoma. N. ROMANCHIKOVA, A. STRODS, J. STRAZDINA, B. STRUMFS, P. TRAPENCIERIS (<i>Riga, Latvia</i>)	6133
<i>Clinical Studies</i>	
Consequences of an Early PSA Response to Enzalutamide Treatment for Japanese Patients with Metastatic Castration-resistant Prostate Cancer. H. KATO, Y. FURUYA, Y. MIYAZAWA, T. MIYAO, T. SYUTO, M. NOMURA, Y. SEKINE, H. KOIKE, H. MATSUI, Y. SHIBATA, K. ITO, K. SUZUKI (<i>Gunma, Japan</i>).....	6141
Imatinib-induced Gastrointestinal Vascular Ectasia in a Patient with Advanced GIST: Case Report and Literature Review. M. ABU-AMNA, H. AWADIE, G. BAR-SELA (<i>Haifa, Israel</i>).....	6151
A Comparative Effectiveness Study of Two Oral Chemotherapy Drugs (UFT vs. Capecitabine) in Neoadjuvant Concurrent Chemoradiotherapy for Patients with Locally Advanced Rectal Cancer. C.-R. CHIEN, W.T.-L. CHEN, H.-M. WANG, T.-W. KE, H.-C. CHIANG, S.-C. CHANG, Y.-C. HUANG, C.-H. LIN, C.-L. HUANG, Y.-C. LIN, T.-W. CHEN, C.-C. LI, K.S.C. CHAO (<i>Taichung, Taiwan, ROC</i>)	6155
Treatment of Advanced Malignant Uterine Perivascular Epithelioid Cell Tumor with mTOR Inhibitors: Single-institution Experience and Review of the Literature. K.D. STARBUCK, R.D. DRAKE, G.T. BUDD, P.G. ROSE (<i>Cleveland, OH, USA</i>)	6161

The Influence of Neoadjuvant Chemotherapy with Docetaxel, Nedaplatin and 5-Fluorouracil After Esophagectomy. S. ASAKA, T. SHIMAKAWA, K. YAMAGUCHI, M. MURAYAMA, A. SHIMAZAKI, T. KATSUBE, Y. NARITAKA (<i>Tokyo, Japan</i>)	6165
Clinical Significance of the Histoculture Drug Response Assay in Breast Cancer. Y. SHINDEN, Y. KIJIMA, M. HIRATA, H. ARIMA, A. NAKAJYO, K. TANOUE, K. MAEMURA, S. NATSUGOE (<i>Kagoshima, Japan</i>)	6173
Sorafenib Combined with Radio-frequency Ablation Compared with Sorafenib Alone in Treatment of Hepatocellular Carcinoma Invading Portal Vein: A Western Randomized Controlled Trial. A. GIORGIO, M.G. MEROLA, L. MONTESARCHIO, F. MEROLA, B. SANTORO, C. COPPOLA, P. GATTI, F. AMENDOLA, A. DI SARNO, A. CALVANESE, P. MATTEUCCI, V. GIORGIO (<i>Salerno; Caserta; Naples; Rome, Italy</i>)	6179
Phase I Study of the Pan-PI3K Inhibitor Buparlisib in Adult Chinese Patients with Advanced Solid Tumors. Y.-L. WU, L. ZHANG, L. TRANDAFIR, T. DONG, V. DUVAL, K. HAZELL, B. XU (<i>Guangzhou; Beijing, PR China; Paris, France; East Hanover, NJ, USA; Basel, Switzerland</i>)	6185
Reduction in Proportion of Senescent CD8+ T Lymphocytes During Chemotherapy of Children with Acute Lymphoblastic Leukemia. V. RUTKAUSKAITĖ, L. RAGELIENĖ, R. MATUZEVIČIENĖ, K. SINKEVIČ, M. MAURICAS, D. CHARACIEJUS (<i>Vilnius, Lithuania</i>)	6195
New Drug and Possible New Toxicity – Squamous Cell Carcinoma Following Imatinib in Patients with Gastrointestinal Stromal Tumors. F. INAYAT, M.W. SAIF (<i>New York, NY; Boston, MA, USA</i>)	6201
Errata	6205